Abstract：
A group of international experts, including hematopathologists, oncologists, and geneticists were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World Health Organization classification system for hematopoietic tumors. After careful deliberation, the group introduced the new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias. This current in-depth review focuses on the ICC-2022 category of JAK2 mutation-prevalent myeloproliferative neoplasms (MPNs): essential thrombocythemia, polycythemia vera, primary myelofibrosis, and MPN, unclassifiable. The ICC MPN subcommittee chose to preserve the primary role of bone marrow morphology in disease classification and diagnostics, while also acknowledging the complementary role of genetic markers for establishing clonality, facilitating MPN subtype designation, and disease prognostication.
摘要：
一群国际专家，包括血液病理学家,肿瘤学家,遗传学家最近被召唤(2021年9月，芝加哥，IL,美国）更新2016/17年世界卫生组织造血系统分类系统。经过仔细考虑，该小组引入了新的髓样肿瘤和急性白血病国际共识分类(ICC).当前的深入审查集中在ICC-2022类别的JAK2突变流行的骨髓增殖性肿瘤（MPN）：原发性血小板增多症，真性红细胞增多症,原发性骨髓纤维化，MPN,无法分类。ICCMPN小组委员会选择保留骨髓形态在疾病分类和诊断中的主要作用，同时也承认遗传标记对建立克隆性的补充作用，促进MPN亚型指定，和疾病预测。
